Uncontrolled fibroblast growth factor (FGF) signaling can lead to human malignancies necessitating multiple layers of self-regulatory control mechanisms. Fibroblast growth factor receptor (FGFR) autoinhibition mediated by the alternatively spliced immunoglobulin (Ig) domain 1 (D1) and the acid box (AB)-containing linker between D1 and Ig domain 2 (D2) serves as the first line of defense to minimize inadvertent FGF signaling. In this report, nuclear magnetic resonance and surface plasmon resonance spectroscopy are used to demonstrate that the AB subregion of FGFR electrostatically engages the heparan sulfate (HS)-binding site on the D2 domain in cis to directly suppress HS-binding affinity of FGFR. Furthermore, the cis electrostatic interaction sterically autoinhibits ligand-binding affinity of FGFR because of the close proximity of HS-binding and primary ligand-binding sites on the D2 domain. These data, together with the strong amino acid sequence conservation of the AB subregion among FGFR orthologs, highlight the universal role of the AB subregion in FGFR autoinhibition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378326 | PMC |
| http://dx.doi.org/10.1016/j.str.2011.10.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Neuro Oncol
September 2017
BioMediTech Institute and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland; Department of Signal Processing, Tampere University of Technology, Tampere, Finland; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Science Center, Tampere University Hospital, Tampere, Finland; Fimlab Laboratories Ltd., Tampere University Hospital, Tampere, Finland; Unit of Neurosurgery, Tampere University Hospital, Tampere, Finland; Pori unit, Tampere University of Technology, Pori, Finland; Department of Pathology, University of Tampere, Tampere, Finland; Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
Article Synopsis
- FGFR inhibitors are showing potential for treating patients with FGFR alterations, particularly in tumors with FGFR3 fusions, which are common in diffuse gliomas.
- In a study of glioma tissue samples, strong FGFR3 expression correlated with the presence of FGFR3 fusions, was more prevalent in females, and was linked to poorer survival outcomes in diffuse astrocytomas.
- The findings suggest that high FGFR3 protein levels could serve as a valuable predictive marker for selecting patients who would benefit from FGFR-targeted therapies.
Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gastroenterology
January 2017
Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China; Cancer Center, Institute of Biomedical Sciences, Fudan University, Shanghai, China. Electronic address:
Background & Aims: No targeted therapies have been found to be effective against hepatocellular carcinoma (HCC), possibly due to the large degree of intratumor heterogeneity. We performed genetic analyses of different regions of HCCs to evaluate levels of intratumor heterogeneity and associate alterations with responses to different pharmacologic agents.
Methods: We obtained samples of HCCs (associated with hepatitis B virus infection) from 10 patients undergoing curative resection, before adjuvant therapy, at hospitals in China.
The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition.
Structure
January 2012
Department of Pharmacology, New York University School of Medicine, 550, First Avenue, New York, NY 10016, USA.
Uncontrolled fibroblast growth factor (FGF) signaling can lead to human malignancies necessitating multiple layers of self-regulatory control mechanisms. Fibroblast growth factor receptor (FGFR) autoinhibition mediated by the alternatively spliced immunoglobulin (Ig) domain 1 (D1) and the acid box (AB)-containing linker between D1 and Ig domain 2 (D2) serves as the first line of defense to minimize inadvertent FGF signaling. In this report, nuclear magnetic resonance and surface plasmon resonance spectroscopy are used to demonstrate that the AB subregion of FGFR electrostatically engages the heparan sulfate (HS)-binding site on the D2 domain in cis to directly suppress HS-binding affinity of FGFR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!